Movement Alert｜Akeso Bio Rises 3.66% in Regular Trading, Ivonescimab Tops Evaluate Global Most Valuable Pipeline Ranking

Market Focus06-29

On June 29, Akeso Bio rose 3.66% in regular trading, trading at 85.8 HKD/share, with turnover of HK$160 million. The stock rebounded from near its 52-week low.

On the news front, global biopharmaceutical analytics firm Evaluate released its latest Global Most Valuable R&D Pipeline ranking, placing Akeso's core product ivonescimab at the top with a risk-adjusted net present value exceeding US$25.2 billion. It is the only independently developed Chinese innovative drug among the top ten. The institution projects its global sales to reach US$8.5 billion by 2032.

This recognition follows ivonescimab's strong clinical momentum, including its landmark OS-positive data from the HARMONi-6 study presented at ASCO, which demonstrated a 34% reduction in mortality risk for squamous NSCLC patients. Multiple brokerages including CICC, CITIC Securities, and Bocom International maintain bullish ratings with target prices significantly above the current level, citing the drug's potential to redefine first-line lung cancer treatment standards globally.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1115007497?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-29 09:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1115007497","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Akeso Bio Rises 3.66% in Regular Trading, Ivonescimab Tops Evaluate Global Most Valuable Pipeline Ranking","media":"Market Focus","content":"<p><p>On June 29, Akeso Bio rose 3.66% in regular trading, trading at 85.8 HKD/share, with turnover of HK$160 million. The stock rebounded from near its 52-week low.</p><p>On the news front, global biopharmaceutical analytics firm Evaluate released its latest Global Most Valuable R&D Pipeline ranking, placing Akeso's core product ivonescimab at the top with a risk-adjusted net present value exceeding US$25.2 billion. It is the only independently developed Chinese innovative drug among the top ten. The institution projects its global sales to reach US$8.5 billion by 2032.</p><p>This recognition follows ivonescimab's strong clinical momentum, including its landmark OS-positive data from the HARMONi-6 study presented at ASCO, which demonstrated a 34% reduction in mortality risk for squamous NSCLC patients. Multiple brokerages including CICC, CITIC Securities, and Bocom International maintain bullish ratings with target prices significantly above the current level, citing the drug's potential to redefine first-line lung cancer treatment standards globally.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Akeso Bio Rises 3.66% in Regular Trading, Ivonescimab Tops Evaluate Global Most Valuable Pipeline Ranking</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Akeso Bio Rises 3.66% in Regular Trading, Ivonescimab Tops Evaluate Global Most Valuable Pipeline Ranking\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-29 09:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 29, Akeso Bio rose 3.66% in regular trading, trading at 85.8 HKD/share, with turnover of HK$160 million. The stock rebounded from near its 52-week low.</p><p>On the news front, global biopharmaceutical analytics firm Evaluate released its latest Global Most Valuable R&D Pipeline ranking, placing Akeso's core product ivonescimab at the top with a risk-adjusted net present value exceeding US$25.2 billion. It is the only independently developed Chinese innovative drug among the top ten. The institution projects its global sales to reach US$8.5 billion by 2032.</p><p>This recognition follows ivonescimab's strong clinical momentum, including its landmark OS-positive data from the HARMONi-6 study presented at ASCO, which demonstrated a 34% reduction in mortality risk for squamous NSCLC patients. Multiple brokerages including CICC, CITIC Securities, and Bocom International maintain bullish ratings with target prices significantly above the current level, citing the drug's potential to redefine first-line lung cancer treatment standards globally.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"","article_id":"1115007497","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1115007497","pubTimestamp":1782697751,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 29, Akeso Bio rose 3.66% in regular trading, trading at 85.8 HKD/share, with turnover of HK$160 million. The stock rebounded from near its 52-week low.On the news front, global...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09926":"康方生物"},"translate_title":"动静提示|康方生物常规交易涨3.66%Ivonescimab登顶评估全球最具价值管线排名","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"On June 29, Akeso Bio rose 3.66% in regular trading, trading at 85.8 HKD/share, with turnover of HK$160 million. The stock rebounded from near its 52-week low.On the news front, global biopharmaceutical analytics firm Evaluate released its latest Global Most Valuable R&D Pipeline ranking, placing Akeso's core product ivonescimab at the top with a risk-adjusted net present value exceeding US$25.2 billion. It is the only independently developed Chinese innovative drug among the top ten. The institution projects its global sales to reach US$8.5 billion by 2032.This recognition follows ivonescimab's strong clinical momentum, including its landmark OS-positive data from the HARMONi-6 study presented at ASCO, which demonstrated a 34% reduction in mortality risk for squamous NSCLC patients. Multiple brokerages including CICC, CITIC Securities, and Bocom International maintain bullish ratings with target prices significantly above the current level, citing the drug's potential to redefine first-line lung cancer treatment standards globally.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1115007497","isCrawlerRequest":true}